Literature DB >> 15967096

The tyrosine kinase pyk2 promotes migration and invasion of glioma cells.

Christopher A Lipinski1, Nhan L Tran, Emmanuel Menashi, Carole Rohl, Jean Kloss, R Curtis Bay, Michael E Berens, Joseph C Loftus.   

Abstract

Glioblastoma multiforme is extraordinarily aggressive due to the propensity of cells to migrate away from the tumor core into the surrounding normal brain. In this report, we investigated the role of proline-rich tyrosine kinase 2 (Pyk2) and FAK with regard to influencing glioma cell phenotypes. Expression of Pyk2 stimulated glioma cell migration, whereas expression of FAK inhibited glioma cell migration and stimulated cell cycle progression. Pyk2 autophosphorylation was necessary, but not sufficient, to stimulate cellular migration. The N-terminal domain of Pyk2 is required for stimulation of migration as an N-terminally deleted variant of Pyk2 failed to stimulate migration, whereas expression of an autonomous Pyk2 N-terminal domain inhibited cell migration. Substitution of the C-terminal domain of Pyk2 with the corresponding domain of FAK stimulated cell migration as effectively as wild-type Pyk2; however, substitution of the N-terminal domain of Pyk2 with that of FAK inhibited cell migration, substantiating that the N-terminal domain of Pyk2 was required to stimulate migration. Silencing of Pyk2 expression by RNA interference significantly inhibited glioma migration. Cell migration was restored on re-expression of Pyk2, but expression of FAK in Pyk2 knockdown cells failed to restore migration. We conclude that Pyk2 plays a central role in the migratory behavior of glioblastomas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15967096      PMCID: PMC1501165          DOI: 10.1593/neo.04712

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  57 in total

Review 1.  Signal transduction from the extracellular matrix--a role for the focal adhesion protein-tyrosine kinase FAK.

Authors:  D D Schlaepfer; T Hunter
Journal:  Cell Struct Funct       Date:  1996-10       Impact factor: 2.212

2.  Glioma cell motility is associated with reduced transcription of proapoptotic and proliferation genes: a cDNA microarray analysis.

Authors:  L Mariani; C Beaudry; W S McDonough; D B Hoelzinger; T Demuth; K R Ross; T Berens; S W Coons; G Watts; J M Trent; J S Wei; A Giese; M E Berens
Journal:  J Neurooncol       Date:  2001-06       Impact factor: 4.130

3.  Inhibition of osteoclast function by adenovirus expressing antisense protein-tyrosine kinase 2.

Authors:  L T Duong; I Nakamura; P T Lakkakorpi; L Lipfert; A J Bett; G A Rodan
Journal:  J Biol Chem       Date:  2000-12-01       Impact factor: 5.157

4.  Molecular determinants of glioma cell migration and invasion.

Authors:  C Wild-Bode; M Weller; W Wick
Journal:  J Neurosurg       Date:  2001-06       Impact factor: 5.115

5.  Transcriptional activation of cyclin D1 promoter by FAK contributes to cell cycle progression.

Authors:  J Zhao; R Pestell; J L Guan
Journal:  Mol Biol Cell       Date:  2001-12       Impact factor: 4.138

Review 6.  Current and future developments in the use of temozolomide for the treatment of brain tumours.

Authors:  R Stupp; M Gander; S Leyvraz; E Newlands
Journal:  Lancet Oncol       Date:  2001-09       Impact factor: 41.316

7.  Suppression of Rac activity induces apoptosis of human glioma cells but not normal human astrocytes.

Authors:  Donna L Senger; Christopher Tudan; Marie-Christine Guiot; Irene E Mazzoni; Gabriele Molenkamp; Richard LeBlanc; Jack Antel; Andre Olivier; G Jackson Snipes; David R Kaplan
Journal:  Cancer Res       Date:  2002-04-01       Impact factor: 12.701

Review 8.  The focal adhesion kinase--a regulator of cell migration and invasion.

Authors:  Christof R Hauck; Datsun A Hsia; David D Schlaepfer
Journal:  IUBMB Life       Date:  2002-02       Impact factor: 3.885

9.  Csk homologous kinase associates with RAFTK/Pyk2 in breast cancer cells and negatively regulates its activation and breast cancer cell migration.

Authors:  Gina D McShan; Radoslaw Zagozdzon; Shin-Young Park; Sheila Zrihan-Licht; Yigong Fu; Shalom Avraham; Hava Avraham
Journal:  Int J Oncol       Date:  2002-07       Impact factor: 5.650

10.  Inhibition of PYK2-induced actin cytoskeleton reorganization, PYK2 autophosphorylation and focal adhesion targeting by FAK.

Authors:  Q S Du; X R Ren; Y Xie; Q Wang; L Mei; W C Xiong
Journal:  J Cell Sci       Date:  2001-08       Impact factor: 5.285

View more
  65 in total

Review 1.  A review of the past, present, and future directions of neoplasia.

Authors:  Alnawaz Rehemtulla; Brian D Ross
Journal:  Neoplasia       Date:  2005-12       Impact factor: 5.715

2.  PYK-2 is tyrosine phosphorylated after activation of pituitary adenylate cyclase activating polypeptide receptors in lung cancer cells.

Authors:  Terry W Moody; Alessia Di Florio; Robert T Jensen
Journal:  J Mol Neurosci       Date:  2012-05-12       Impact factor: 3.444

3.  Expression patterns and action analysis of genes associated with hepatitis virus infection during rat liver regeneration.

Authors:  Li-Juan Su; Guang-Wei Ding; Zhi-Li Yang; Shou-Bing Zhang; Yu-Xiu Yang; Cun-Shuan Xu
Journal:  World J Gastroenterol       Date:  2006-12-21       Impact factor: 5.742

4.  RhoC promotes metastasis via activation of the Pyk2 pathway in prostate cancer.

Authors:  Megumi Iiizumi; Sucharita Bandyopadhyay; Sudha K Pai; Misako Watabe; Shigeru Hirota; Sadahiro Hosobe; Taisei Tsukada; Kunio Miura; Ken Saito; Eiji Furuta; Wen Liu; Fei Xing; Hiroshi Okuda; Aya Kobayashi; Kounosuke Watabe
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

5.  Pyk2 activation triggers epidermal growth factor receptor signaling and cell motility after wounding sheets of epithelial cells.

Authors:  Ethan R Block; Michael A Tolino; Jes K Klarlund
Journal:  J Biol Chem       Date:  2010-03-09       Impact factor: 5.157

6.  Comparative Analysis of Gene Expression Profiles Involved in Calcium Signaling Pathways Using the NLVH Animal Model of Schizophrenia.

Authors:  Alma Genis-Mendoza; Ileana Gallegos-Silva; Carlos Alfonso Tovilla-Zarate; Lilia López-Narvaez; Thelma Beatriz González-Castro; Yazmín Hernández-Díaz; Mavil López-Casamichana; Humberto Nicolini; Sandra Morales-Mulia
Journal:  J Mol Neurosci       Date:  2017-12-06       Impact factor: 3.444

Review 7.  Targeting Pyk2 for therapeutic intervention.

Authors:  Christopher A Lipinski; Joseph C Loftus
Journal:  Expert Opin Ther Targets       Date:  2010-01       Impact factor: 6.902

8.  Structural conservation in band 4.1, ezrin, radixin, moesin (FERM) domains as a guide to identify inhibitors of the proline-rich tyrosine kinase 2.

Authors:  Nathalie Meurice; Lei Wang; Christopher A Lipinski; Zhongbo Yang; Christopher Hulme; Joseph C Loftus
Journal:  J Med Chem       Date:  2010-01-28       Impact factor: 7.446

9.  Inhibition of the focal adhesion kinase and vascular endothelial growth factor receptor-3 interaction leads to decreased survival in human neuroblastoma cell lines.

Authors:  Elizabeth A Beierle; Xiaojie Ma; Jerry E Stewart; Michael Megison; William G Cance; Elena V Kurenova
Journal:  Mol Carcinog       Date:  2012-10-12       Impact factor: 4.784

10.  Cell aggregation induces phosphorylation of PECAM-1 and Pyk2 and promotes tumor cell anchorage-independent growth.

Authors:  Xing Zhang; Li-hua Xu; Qiang Yu
Journal:  Mol Cancer       Date:  2010-01-14       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.